Last reviewed · How we verify
Anti-PD1 Monoclonal Antibody
Inhibits PD-1 receptor
Inhibits PD-1 receptor Used for Non-small cell lung cancer, Melanoma, Kidney cancer.
At a glance
| Generic name | Anti-PD1 Monoclonal Antibody |
|---|---|
| Also known as | Anti-PD-1 Monoclonal Antibody |
| Sponsor | City of Hope Medical Center |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
PD-1 inhibitors are a class of immunotherapy drugs that work by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer
- Melanoma
- Kidney cancer
Common side effects
- Pneumonitis
- Colitis
- Hypothyroidism
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma (PHASE2)
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (PHASE1)
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors (PHASE1, PHASE2)
- Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (PHASE1)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-PD1 Monoclonal Antibody CI brief — competitive landscape report
- Anti-PD1 Monoclonal Antibody updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI